Laddar...
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases. Acalabrutinib is a second generation, highly selective, potent, covalent BTK inhibitor that exhibits minimal off-target activity...
Sparad:
| I publikationen: | Front Oncol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Frontiers Media S.A.
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8162209/ https://ncbi.nlm.nih.gov/pubmed/34055635 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.668162 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|